ProMIS Neurosciences reports FY2023 net loss $13.2M, cash $12.6M; PMN310 Phase 1a data on track for mid-2024

ProMIS Neurosciences Inc.

2024-Q1 EPS reported -$0.19

Cash and cash equivalents $12.6M at Dec 31, 2023, up from $5.9M; Q3 2023 PIPE raised $20.4M gross.
Net loss $13.2M for FY2023 vs $18.1M in FY2022; R&D expenses $7.9M vs $16.1M.
Phase 1a trial of PMN310 for Alzheimer's dosed Nov 2023; top-line safety/PK data expected mid-2024.
Lead vaccine candidate PMN400 selected for synucleinopathies (MSA, Parkinson's) in Jan 2024.
Neil Warma appointed interim CEO in Jan 2024; US/international patent allowances for AD antibody in Mar 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ProMIS Neurosciences Inc. reported the fiscal year ended December 31, 2023 results: net income $13.2 million.

Period: the fiscal year ended December 31, 2023
Net income: $13.2 million
Result: reported results

Exact text from the filing

Net loss was $13.2 million for the full year ended December 31, 2023, compared to a net loss of $18.1 million for full year in 2022.

View on SEC.gov

324 earnings releases filed in the last 30 days. Browse all earnings releases →

ProMIS Neurosciences Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-004527

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.